Seres Therapeutics, Inc.

Contributing Author

Recent Articles by Seres Therapeutics, Inc.

Oct-30	Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 MCRB GlobeNewswire
Oct-29	Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 MCRB GlobeNewswire
Oct-14	Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant MCRB GlobeNewswire
Sep-23	Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway MCRB GlobeNewswire
Aug-27	Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference MCRB GlobeNewswire
Aug-06	Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates MCRB GlobeNewswire
Jul-22	Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 MCRB GlobeNewswire
Jul-22	Seres Therapeutics Announces Leadership Transition MCRB GlobeNewswire
May-27	Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting MCRB GlobeNewswire
May-07	Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates MCRB GlobeNewswire